Curriculum Vitae

Hideyuki Sato, Ph. D.

Research Assistant Professor, Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan

E-mail: h.sato@u-shizuoka-ken.ac.jp

1. Birth

August 2, 1985

2. Education

B. Sc.	Pharmaceutical Sciences (Pharmacokinetics and Pharmacodynamics)	University of Shizuoka	2008
M. Sc.	Pharmaceutical Sciences (Pharmacokinetics and Pharmacodynamics)	University of Shizuoka	2010
Ph. D.	Pharmaceutical Sciences (Pharmacokinetics and Pharmacodynamics)	University of Shizuoka	2015

3. Job/Research Experience

2010-2014	Nippon Shinyaku Co. Ltd. (Research scientist, CMC Research and Development department)
2014-2015	Osaka University of Pharmaceutical Sciences (Assistant, Laboratory of Formulation Design and Pharmaceutical Technology)
2015-present	University of Shizuoka (Research assistant professor, Faculty of Pharmaceutical Sciences)

4. Recent research interests

My current research interests include (1) Pharmacokinetic control of poorly water soluble compounds with strategic modification of physicochemical properties, (2) Development of a novel formulation for avoidance of adverse side effect.

5. Publication (As of Aug. 5, 2015)

Original Articles (16)

1) Kadota K., Ehara M., Fujimori M., Sato H., Tozuka Y.
[Quantification of the amorphous content of ursodeoxycholic acid by pulsed NMR] *J. Pharm. Sci. Technol., Jpn.*, In press (2015)

2) Satoshi Tanida, Tsuyoshi Kurokawa, Hideyuki Sato, Kazunori Kadota, Yuichi Tozuka
[Evaluation for micellization mechanism of an amphipathic graft copolymer with enhanced solubility of ipriflavoner] *Chem pharm bull.,* In press (2015)

3) Kadota K., Otsu S., Fujimori M., Sato H., Tozuka Y. [Soluble hydrolysis-resistant composite formulation of curcumin containing α-glucosyl hesperidin and polyvinylpyrrolidone] *Advanced powder Technology*, In press (2015)

4) Fujimori M., Kadota K., Kato K., Seto Y., Onoue S., Sato H., Ueda H., Tozuka Y. [Low hygroscopic spray-dried powders with trans-glycosylated food additives for the enhanced solubility and oral bioavailability of a hydrophobic flavone] *Food Chem.*, **190**:1050-1055 (2016)

5) Sato H, Fujimori M, Suzuki H, Kadota K, Shirakawa Y, Onoue S, Tozuka Y [Absorption improvement of tranilast by forming highly soluble nano-size composite structures associated with α-glucosyl rutin via spray drying.] *Eur J Pharm Biopharm.,* **92:**49-55 (2015)

6) Sato H, Ogawa K, Kojo Y, Suzuki H, Mizumoto T, Onoue S [Physicochemical stability study on cyclosporine A loaded dry-emulsion formulation with enhanced solubility.] *Chem pharm bull.,* **63**:54-58 (2015)

7) Fujimori M, Kadota K, Shimono K, Shirakawa Y, Sato H, Tozuka Y [Enhanced solubility of quercetin by forming composite particles with transglycosylated materials.] *J Food Engineering.*, **149**:248–254 (2015)

8) Onoue S, Suzuki H, Kojo Y, Matsunaga S, Sato H, Mizumoto T, Yuminoki K, Hashimoto N, Yamada S. [Self-micellizing solid dispersion of cyclosporine A with improved dissolution and oral bioavailability.] *Eur J Pharm Sci.*, **62**:16-22 (2014)

9) Sato H, Ogawa K, Kojo Y, Kawabata Y, Mizumoto T, Yamada S, Onoue S [Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy.] *Int J Pharm.,* **448**:282-9 (2013)

10) Sato H, Kawabata Y, Yuminoki K, Hashimoto N, Yamauchi Y, Ogawa K, Mizumoto T,
Yamada S, Onoue S [Comparative studies on physicochemical stability of cyclosporine A-loaded amorphous solid dispersions.] *Int J Pharm.*, **426**:302-6 (2012)

11) Onoue S, Sato H, Ogawa K, Kojo Y, Aoki Y, Kawabata Y, Wada K, Mizumoto T, Yamada S [Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.] *Eur J Pharm Biopharm.,* **80**:54-60 (2012)

12) Kawabata Y, Aoki Y, Matsui T, Yamamoto K, Sato H, Onoue S, Yamada S [Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.] *Eur J Pharm Biopharm.*, **77**:178-81 (2011)
13) Misaka S, Sato H, Aoki Y, Mizumoto T, Onoue S, Yamada S [Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis.] *Peptides.,* **32**:401-7 (2011)
14) Onoue S, Sato H, Ogawa K, Kawabata Y, Mizumoto T, Yuminoki K, Hashimoto N, Yamada S [Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.] *Int J Pharm.,* **399**:94-101 (2010)
15) Onoue S, Aoki Y, Kawabata Y, Matsui T, Yamamoto K, Sato H, Yamauchi Y, Yamada S [Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases.] *J Pharm Sci.,* **100**:622-33 (2011)
16) Hatanaka J, Chikamori H, Sato H, Uchida S, Debari K, Onoue S, Yamada S [Physicochemical and pharmacological characterization of alpha-tocopherol-loaded nano-emulsion system.] *Int J Pharm.,* **396**:188-93 (2010)
17) Misaka S, Sato H, Yamauchi Y, Onoue S, Yamada S [Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats.] *Eur J Pharm Sci.,* **37**:469-76 (2009)
18) Onoue S, Misaka S, Ohmori Y, Sato H, Mizumoto T, Hirose M, Iwasa S, Yajima T, Yamada S [Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability.] *Eur J Pharm Biopharm.,* **73**:95-101 (2009)
19) Onoue S, Sato H, Kawabata Y, Mizumoto T, Hashimoto N, Yamada S [In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy.] *J Control Release.,* **138**:16-23 (2009)